(AOF) – In 2023, Virbac recorded a consolidated net profit down 0.2% to 121.1 million euros. Current operating income before depreciation of assets resulting from acquisitions of the veterinary laboratory increased by 0.8% to 188.1 million euros, showing a margin of 15.1% compared to 15.3% in 2022. It is stood at 15.3% at constant exchange rates. Already published, annual turnover reached 1.24 billion euros, up 2.5% on a published basis and 4.9% at constant exchange rates.
Finally, the distribution of a net dividend of 1.32 euros per share for the 2023 financial year will be proposed to the next general meeting of shareholders. It is stable compared to 2022.
In 2024, at constant exchange rates and scope, Virbac anticipates a ratio of current operating income, before amortization of assets resulting from acquisitions (adjusted Ebit), to turnover of around 15% and growth in turnover between 4% and 6%.
The group has reaffirmed its ambition to achieve an adjusted Ebit ratio of 20% by 2030. In this regard, Virbac plans in the coming years to gradually restore its investments in R&D to the normative and historical level of the group, i.e. around 2 points below the percentage of R&D on turnover for 2024.
Furthermore, excluding acquisitions, its cash position should improve by 30 million euros, taking into account the investments planned over the period, estimated at around 100 million euros, and the acceleration of our R&D efforts.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
